Login to Your Account

4SC, Leo Pharma Ink $125M Preclinical Deal in Psoriasis

By Cormac Sheridan
Staff Writer

Wednesday, February 27, 2013
4SC AG could earn up to €96 million (US$125 million) in option and milestone payments arising out of a preclinical drug development deal in inflammatory skin disease with Leo Pharma A/S, as well as double-digit royalties on eventual product sales.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription